Table 1

Clinical characteristics of the included individuals

DonorRecipient
SexAge (years)Weight (kg)Height (cm)SmokerCause of deathSexAge (years)Underlying diseaseCMARSType of TxMaintenance therapy
F3580170YesCerebral haemorrhageM50IPF0DCiclosporin-MMF-Prednisolon
F3457174NoOtherM58IPF0.11DTacrolimus-Azathioprin-Prednisolon
F5270170NoTraumaM55IPF0.33DTacrolimus-Azathioprin-Prednisolon
F5873170NoCerebral haemorrhageM58Sarcoidosis0DCiclosporin-MMF-Prednisolon
F4765170NoCerebral haemorrhageM59IPF0.43DTacrolimus-Everolimus-MMF- Prednisolon
F3775170NDTraumaM43Sarcoidosis0.375DCiclosporin-MMF-Prednisolon
M1975180NDTraumaF49A1ATD0.285DTacrolimus-MMF-Prednisolon
M5462172YesCerebral haemorrhageF41Emphysema0.36SCiclosporin-MMF-Prednisolon
F3365170NDOtherM60IPF0.375DCiclosporin-MMF-Prednisolon
M4585175NDCerebral haemorrhageF56Emphysema0.428SCiclosporin-MMF-Prednisolon
  • A1ATD, α-1-antitrypsin deficit; CMARS, cumulative mean average rejection score; D, double; F, female; IPF, idiopathic pulmonary fibrosis; M, male; MMF, mycophenolate mofetil; ND, not determined; S, single; Tx, transplantation.